Studies have shown that alterations in the abundance of specific gut microbes, such as Firmicutes and Bacteroidetes, are associated with increased blood pressure in hypertension models.

Furthermore, diet influences the composition of the gut microbiota , which can impact blood pressure regulation. Different dietary patterns result in distinct microbial profiles, known as enterotypes, which may influence the development of hypertension.

Understanding these interactions and their influence on blood pressure can provide valuable insights for managing hypertension and developing targeted interventions. Research suggests that certain probiotics hold promise in lowering blood pressure levels.

In particular, probiotics containing Lactobacillus strains have shown positive effects in reducing blood pressure. A meta-analysis of randomized, controlled trials revealed that consuming probiotics can result in a modest decrease in both systolic and diastolic blood pressure. While further research is still needed to determine the optimal strains, dosages, and duration of probiotic supplementation for blood pressure management, the current evidence underscores the potential benefits of incorporating probiotics, particularly those containing Lactobacillus strains, into one's daily routine.

By embracing these probiotics, individuals may take proactive steps towards maintaining healthy blood pressure levels and supporting overall cardiovascular health. Functional medicine takes a comprehensive and personalized approach to address gut health.

Unlike conventional medicine, which often focuses on symptom management, functional medicine aims to identify and address the root causes of gut imbalances. By delving into the underlying factors contributing to gut issues, functional medicine practitioners can design tailored treatment strategies to optimize gut function and promote overall well-being.

One key aspect of functional medicine's approach to gut health is the recognition of the gut microbiome's significant impact on overall health, including cardiovascular health.

The gut microbiome refers to the community of microorganisms residing in our intestines. Functional medicine utilizes advanced testing to assess the balance and diversity of the gut microbiota, identify potential dysbiosis imbalance , and evaluate markers of gut inflammation and permeability.

Functional medicine's approach to gut health differs from conventional medicine in that it aims to address the root causes of gut imbalances rather than solely managing symptoms. Functional medicine recognizes the interconnectedness of various body systems and the impact of factors like diet, lifestyle, genetics, and comorbid conditions on gut health.

By considering the centrality of gut health in preventing and treating conditions like cardiovascular disease, functional medicine practitioners can design personalized interventions to restore gut balance and positively impact overall health outcomes.

In contrast, conventional medicine often focuses on prescribing medications to manage symptoms without necessarily addressing the underlying causes.

While conventional medicine certainly has its merits, functional medicine offers a more holistic and individualized approach to gut health, taking into account the unique needs and circumstances of each patient. Functional medicine practitioners utilize various tests to assess gut health and gain insights into its impact on overall well-being.

Two commonly used tests in functional medicine for assessing gut health are microbiome analysis and comprehensive stool analysis. Microbiome analysis, such as the GI-MAP by Diagnostic Solutions , employs PCR technology to screen for over 50 beneficial and harmful bacteria, viruses, parasites, and yeast present in the gut.

This analysis provides a comprehensive understanding of the gut microbiome's composition and diversity. Identifying the presence of specific microorganisms can help assess for dysbiosis, an imbalance in the gut microbiota that can contribute to various health issues.

Additionally, microbiome analysis evaluates markers of digestion, absorption, intestinal inflammation, and microbial metabolism, offering valuable insights into gut health as it relates to systemic well-being. Comprehensive stool analysis, such as the GI Effects Comprehensive Profile by Genova Diagnostics , provides a more detailed assessment of gut health.

This test not only analyzes the microbiome's diversity and composition but also measures metabolites like short-chain fatty acids and inflammatory markers such as calprotectin. These metabolites and markers give insights into the overall health of the gut and can help identify conditions like dysbiosis and intestinal inflammation.

Furthermore, an optional add-on for assessing intestinal permeability, such as measuring zonulin levels, can indicate the presence of leaky gut when elevated. These tests offer valuable insights into the gut's microbial ecosystem, as well as markers of inflammation and intestinal permeability.

By understanding the composition of the gut microbiome, identifying potential imbalances and dysfunctions, and assessing markers of gut health, functional medicine practitioners can develop personalized treatment strategies to restore balance and optimize gut function.

These strategies may include dietary modifications, probiotics, and lifestyle changes, all aimed at improving gut health and positively impacting overall well-being, particularly cardiovascular health. The composition of the gut microbiome is highly individualized and can be influenced by various factors, with diet playing a significant role.

It is hypothesized that these enterotypes may impact the development of hypertension in different ways and to varying degrees. For example, certain enterotypes may promote an inflammatory state or produce metabolites that affect blood pressure regulation.

While the gut microbiome appears to have a role in the development of hypertension, further research is needed to fully understand the mechanisms involved and develop targeted interventions. It is essential to explore the specific interactions between the gut microbiota, dietary patterns, genetic factors, and environmental influences to gain a comprehensive understanding of their combined impact on blood pressure regulation.

This knowledge could potentially lead to personalized interventions that target the gut microbiome to prevent or manage hypertension more effectively. Cloyd, Dr. A Functional Medicine Hypertension Protocol. Rupa Health.

Gut Microbiome Testing: How to Use This Powerful Tool in Practice. What is the Gut Microbiome? Functional Medicine for Digestive Wellness in Patients with Heart Disease. Cloyd, J. How to Heal Your Gut Naturally With Functional Nutrition.

DeCesaris, L. What Is Gut Dysbiosis? Jing Lv, Wang, J. Alterations of gut microbiota are associated with blood pressure: a cross-sectional clinical trial in Northwestern China.

Journal of Translational Medicine , 21 1. Jose, P. Gut microbiota in hypertension. Current Opinion in Nephrology and Hypertension , 24 5 , — Neibling, Dr. Why Functional Medicine Practitioners Focus on Gut Health. Qi, D. The effect of probiotics supplementation on blood pressure: a systemic review and meta-analysis.

Lipids in Health and Disease , For more research-backed information about the microbiome and how it affects your health, please visit our dedicated hub.

Each week, journals publish many study papers that examine how these microscopic visitors might play a role in health and disease.

However, it is becoming increasingly clear that the bacteria in our gut can open new avenues in our understanding of a wide range of conditions.

This Spotlight focuses on their role in hypertension. Elevated blood pressure is a risk factor for cardiovascular disease and affects almost 1 in 3 adults in the United States.

Because of this, it is vital that medical scientists unearth the various mechanisms that underpin blood pressure regulation. Although researchers have established certain risk factors for hypertension — such as smoking, obesity , and drinking excessive amounts of alcohol — there appears to be more to the condition.

adults with hypertension have a treatment-resistant form of the condition, wherein medications do not bring blood pressure down to a healthful level. Also, lifestyle interventions do not work for everyone.

Some scientists are considering dysfunction of the immune system and autonomic nervous system. A relatively new addition to this list of potential risk factors is gut dysbiosis, which refers to an imbalanced microbial community. A study in the journal Microbiome analyzed the gut bacteria of 41 people with ideal blood pressure levels, 99 individuals with hypertension, and 56 people with prehypertension.

Prehypertension refers to high blood pressure that is not yet high enough for a person to receive a diagnosis of hypertension. People in this range have an increased risk of developing hypertension in the future.

They found that in the participants with prehypertension or hypertension, there was a reduction in the diversity of gut bacteria.

In particular, species such as Prevotella and Klebsiella tended to be overgrown. Next, the scientists transplanted fecal matter from the participants into germ-free mice, which are animals that lack gut bacteria.

The mice that received fecal matter from people with hypertension also developed hypertension. Conversely, the authors of a study in the journal Frontiers in Physiology transplanted feces from mice without hypertension into mice with hypertension.

This resulted in a reduction in blood pressure in the mice with hypertension. Another study investigated the bacterial residents of pregnant women with obesity and overweight pregnant women, both of whom are at increased risk of hypertension. They found that in both sets of participants, bacteria of the genus Odoribacter were significantly rarer.

Although evidence is mounting that gut bacteria can influence hypertension, most of the studies to date have been observational. This means that it has not been possible to determine whether changes in gut bacteria influence blood pressure, or whether hypertension or the factors that produce it alter gut bacteria.

Although the gut and blood pressure might not seem like obvious companions, the connection is not, perhaps, so surprising. Many of the factors that increase the risk of hypertension — such as the consumption of alcohol and salty food — enter the body through the digestive system.

Nutrients, along with certain chemicals that bacteria produce, have the opportunity to enter the blood supply; once in circulation, the body is their oyster.

Also, the gastrointestinal tract hosts a number of processes that have the potential to play a role in hypertension, including metabolism, the production of hormones, and a direct connection with the nervous system.

Some researchers believe that one of the links between the gut and hypertension could be short chain fatty acids SCFAs. Some gut bacteria produce these molecules as they digest dietary fiber.

SCFAs affect a range of physiological processes, one of which appears to be blood pressure. Backing this theory up, one study found differences in gut bacterial populations between participants with and without hypertension. Individuals with higher blood pressure had lower levels of certain species that produce SCFAs, including Roseburia spp.

and Faecalibacterium prausnitzii. One paper in the journal Hypertension investigated the role of gut bacteria in sleep apnea-induced hypertension.

The scientists simulated sleep apnea in rats. To so do, they fed half of the rats a standard diet and the other half a high fat diet. Hypertension only appeared in the rats that ate the fatty diet. Finally, the scientists transplanted bacteria from the hypertensive rats into the rats who ate a normal diet and demonstrated normal blood pressure.

Most likely, if gut bacteria truly do have the power to produce hypertension, it is likely to be via a number of interlinked routes. Scientists have several theories. For instance, some experts see a role for the autonomic nervous system.

Studies have shown that hypertension is associated with increased sympathetic nerve activity a branch of the autonomic nervous system. This increases gut permeability. This change in permeability impacts the gut environment and alters the microbiome.

At the same time, bacterial products can pass more easily into the blood. Interestingly, other factors — including smoking tobacco and being stressed — also alter the sympathetic system. This could help provide further reasons why these factors can also lead to cardiovascular changes.

Designing a probiotic that reliably reduces high blood pressure will take some time, but some researchers are looking at this option. A meta-analysis examined the effect of probiotic fermented milk on blood pressure.

Sensory neurons of the GPNs are localized to the petrous ganglion. An inverse relationship was observed between the neuron number of the petrosal ganglion and blood pressure values, with potential implications for the study of hypertension etiology [ 70 ]. Nifedipine, a calcium channel antagonist, exerts its antihypertension role partly through stimulating the GPNs [ 71 ].

This antihypertensive effect decreased after GPN denervation in accordance with the increased degeneration of neurons in the petrous ganglion [ 71 ]. Salt taste sensitivity is the capacity to identify the flavor of salt. It is possible that salt taste sensitivity can influence salt consumption, which is associated with hypertension [ 72 ].

An epidemiological study found salt taste impairment was associated with increased prevalence of hypertension in Japanese women [ 73 ]. The high salt threshold group also had significantly higher hour urinary sodium [ 74 ]. Several studies have shown elevated thresholds for salt perception in hypertensive patients [ 72,75,76 ].

After adjusting for gender, age, sedentary lifestyle and BMI, adolescents with high salt taste thresholds have higher diastolic blood pressure [ 77 ].

Another study showed a negative correlation between blood pressure and salty taste sensitivity in adolescents [ 78 ]. Angiotensin II AngII , a major mediator of body fluid and sodium homeostasis, was found to modulate salty and sweet taste sensitivities.

This AngII modulation critically influenced GI ingestion behaviors in mice [ 79 ]. The specific inhibition of amiloride-sensitive salt taste sensitivity by AngII may contribute to increased sodium intake [ 79 ].

AngII may also contribute to increased energy intake by enhancing sweet responses [ 79 ]. Increased levels of aldosterone and AngII were associated with inhibition of salty taste sensitivity [ 80 ]. In addition, some hypotensive drugs can decrease taste sensitivity or result in total loss of taste perception [ 81 ].

Taste perception is also modulated by gastric hormones, such as ghrelin [ 82 ]. These results suggested that abnormal taste perception might be involved in hypertension by increasing salt intake. The human gut is densely populated by trillions of symbiotic microbes. Symbiotic microbes provide protection from invading pathogens and aid in nutrient absorption [ 83 ].

Diet is regarded as the main factor contributing to the make-up of the gut microbiota, and the gut microbes influence eating activity [ 84 ]. The link between the gut microbes and the development of cardiometabolic disease is a popular topic [ 85 ].

Studies in both humans and mice show that gut microbes influence metabolic processes, such as energy extraction from food, and should be regarded as an environmental factor that contributes to obesity and its comorbidities, such as diabetes and cardiovascular disease [ 85 ].

Alterations in gut microbiota can occur as a result of changes in the composition or function of the gut microbiota as well as microbiota-host interactions [ 86 ].

It is well known that changes in food production and preparation profoundly impact gut microbes [ 84 ]. Indeed, long-term dietary habits show a considerable effect on human gut microbiota. One study showed that children in a rural African village who consumed a high-fiber diet had low levels of Firmicutes and increased levels of Bacteroidetes in their fecal microbiota compared with Italian children, who consumed a modern Western diet and had high levels of Enterobacteriaceae [ 84 ].

The level of short-chain fatty acids was higher in the children from the rural African village, and short-chain fatty acids have profound effects on gut health, as energy sources, inflammation modulators, vasodilators and regulators of gut motility and wound healing [ 84 ].

These alterations in gut microbiota composition may contribute to the host's metabolic phenotype [ 85 ]. Furthermore, obese humans and obese mice had different gut microbe populations when compared with those of lean individuals [ 87,88 ]. The mix of gut microbes from obese individuals could extract a small amount of calories from what would normally be undigested food, and these calories may contribute to weight gain [ 87,88 ].

Mice lacking Toll-like receptor 5 TLR5 , which is a component of the innate immune system expressed in the gut mucosa, exhibited hyperphagia and had many characteristics of metabolic syndrome, including hyperlipidemia, hypertension, insulin resistance, and obesity [ 91 ].

These metabolic abnormalities correlated with changes in the gut microbiota [ 91 ]. By transferring the gut microbiota from TLR5-deficient mice to WT germ-free mice, many features of metabolic syndrome were recapitulated [ 91 ]. These results support the view that the gut microbiota contribute to metabolic disturbances.

Currently, how gut microbiota contribute to the development of hypertension remains unknown Figure 1 AND Figure 2. Impaired salt taste sensitivity is associated with excessive salt intake.

Gut hormones regulate cardiometabolic homeostasis. Increased sympathetic activity and impaired sympathoinhibition have been tightly linked to the development of hypertension.

Gut microbes effect host's metabolic processes and contribute to metabolic disorders. Multiple dietary factors affect metabolic profiles and BP regulation through gastrointestinal absorption.

Probiotic consumption could improve obesity, diabetes, hypercholesterolemia, and hypertension, through modifying gut microbiota. Changes in gut hormones, insulin sensitivity, gut microbiota, and inhibited sympathetic nerve activity may contribute to the reduced BP following metabolic surgery.

Currently, therapeutic lifestyle changes, medication and interventional treatment are the three major management strategies for hypertension.

However, these treatments are closely associated with gastrointestinal intervention. A wealth of evidence strongly supports the fact that multiple dietary factors affect BP [ 10 ].

It is noteworthy that these dietary factors mediate their effect through gastrointestinal absorption. Nutritional compounds might modulate the development of metabolic diseases [ 92 ]. Nutritional approaches, such as increased vegetable, fruit and potassium consumptions as well as reduced sodium chloride and alcohol intake, have been recommend to prevent and treat hypertension.

The well-known trial Dietary Approaches to Stop Hypertension DASH has shown that healthy dietary factors such as a diet low in fats and rich in fiber and high in low-fat dairy products, fruits, and vegetables play an important role in hypertension control.

Thus, lifestyle modifications should be the initial treatment strategy for lowering BP [ 93 ]. In addition, some specific nutrients were found to benefit BP control. Loss of zinc homeostasis may participate in BP regulation and hypertension pathogenesis [ 94 ].

Dietary zinc intake was inversely associated with SBP in obese Korean women after adjusting for body weight, energy intake and sodium consumption [ 95 ].

Oral administration of zinc also improved type 2 diabetes and metabolic syndrome in mice [ 96 ]. In observational studies, significant inverse associations between BP and magnesium, potassium, and calcium consumption have also been reported [ 97 ].

Capsaicin, a major pungent ingredient in hot peppers, which is consumed worldwide, exerts beneficial effects on cardiometabolic diseases. The transient receptor potential vanilloid 1 TRPV1 cation channel activated by capsaicin exerts antihypertension effects in both genetically hypertensive rats and high-salt-intake induced hypertensive mice [ 98,99, ].

Importantly, dietary capsaicin was shown to further reduce hypertension-related cardio cerebrovascular risks [ ], delay the onset of stroke in stroke-prone spontaneously hypertensive rats, and attenuate cardiac hypertrophy in high-salt fed mice [ , ].

Furthermore, TRPV1 activation by capsaicin can also improve glucose and lipid metabolic profiles and attenuate hyperglycemia- and hyperlipemia-induced vascular damages in rodents [ ,,,, ].

Activation of TRPV1 by dietary capsaicin contributes to vascular and metabolic benefits and may represent a promising target for therapeutic intervention of cardiometabolic diseases.

Menthol, a compound in mint with a naturally cold sensation, was shown to improve flow-mediated dilatation and moderately lower BP levels in prehypertensive individuals after an 8-week consumption period [ ]. Dietary curcumin, which has an antioxidant effect, can improve aging-related cerebrovascular dysfunction in rodents [ ].

Resveratrol, a natural polyphenol in grapes and red wine, has been shown to have beneficial effects on glucose and lipid metabolism, vascular function, and antioxidative properties [ , ].

A Mediterranean diet rich in resveratrol is associated with a significantly reduced risk of cardiovascular diseases [ ]. Therefore, increasing healthy dietary factors and preventing harmful dietary intake through the gastrointestinal tract are key steps for the prevention of metabolic hypertension.

Interactions between gut microbiota and cardiometabolic diseases have received increased attention in recent years. The host's metabolic abnormalities are correlated with changes in the gut microbiota.

Probiotic consumption is commonly used to rebalance disturbed intestinal microbiota and to treat gastrointestinal disorders. Recent studies have shown that probiotics may improve obesity, diabetes, hypercholesterolemia, and arterial hypertension through modifications of gut microbiota [ ].

A meta-analysis of randomized, controlled trials demonstrated that probiotic administration may improve BP control in humans, reducing SBP by 3. Subgroup analysis suggested that probiotic consumption may regulate BP by a modest degree [ ].

Probiotic fermented milk, a product obtained from the fermentation of milk by the action of suitable microorganisms, may exert protective effects against type 2 diabetes, cardiovascular diseases and stroke [ ]. Probiotic yogurt consumption also has an effect on lipid metabolism, significantly reducing total cholesterol and LDL-cholesterol levels [ ].

Another meta-analysis of randomized placebo-controlled trials involving participants suggested that probiotic fermented milk could lower BP in prehypertension and hypertension individuals [ ].

Soy milk fermented with specific probiotics could enhance NO production and the coupled state of eNOS, which leads to vasodilation [ ]. However, beneficial effects of gut microbiota modification on hypertension need to be further validated through more clinical trials and experimental studies.

Gastrointestinal bypass surgery, also called metabolic surgery, is currently an effective treatment for morbid obesity and its related comorbidities [ ]. Metabolic surgery includes gastric banding, gastric bypass, gastroplasty, biliopancreatic diversion and duodenal switch.

Effective weight loss can be achieved in morbidly obese patients after metabolic surgery [ ,, ]. Mounting reports have also shown that a substantial majority of patients with diabetes, hyperlipidemia, obstructive sleep apnea, and hypertension are resolved or remitted after they underwent metabolic surgery [ ,,, ].

A meta-analysis reported that hypertension was resolved in Furthermore, short- and long-term control rates of hypertension were higher in the surgery group compared with the non-surgical group [ ]. The mechanisms by which metabolic surgery ameliorates hypertension are not fully understood.

Several studies have suggested that BP reduction might be related to metabolic surgery-induced weight loss [ , ]. However, clinical observations found that a quick reduction in BP could be achieved before a remarkable reduction in weight loss [ ].

Thus, the beneficial effect of metabolic surgery on BP is independent of weight loss and is also independent of surgery-related trauma and energy intake [ ]. Although some studies showed that changes in gut hormones, insulin sensitivity, reduction in salt intake, increased urinary sodium excretion, and changes in gut microbiota might contribute to reduced high blood pressure following metabolic surgery, the underlying mechanisms remain poorly understood [ 21,22,23,24,25,26, ].

Recently, we showed that metabolic surgery efficiently lowered blood pressure and improved cardiovascular dysfunction and remodeling through inhibition of both peripheral and central sympathetic nerve activity in diabetic hypertensive patients and genetic hypertensive rats [ ].

Thus, metabolic surgery might be a novel treatment strategy for the management of hypertension, especially for hypertensive patients with metabolic disorders [ ], table 1.

Efficacy for improvement in hypertension by metabolic surgeries [ , ]. The gastrointestinal tract is not only an organ involved in nutrient digestion and absorption but also has a critical role in the pathogenesis of cardiometabolic diseases, such as metabolic hypertension.

Daily dietary factors and enterogenous factors such as GI hormones, liver insulin sensitivity, GI nerve innervations, and gut microbiota participate in the regulation of BP through different pathways and mechanisms. However, GI intervention through healthy dietary approaches, gut microbiota modification, and metabolic surgery profoundly improve or remit cardiometabolic disease, including hypertension.

Thus, numerous clinical and basic studies indicate that GI tract could be one of organs that initiate the development of metabolic hypertension. Meanwhile, more future investigations are necessary to validate this novel concept.

We thank Dr. Li Li for creating the figures of the manuscript. This review was supported by the National Basic Research Program of China CB, and CB , The National Natural Science Foundation of China , , and , and supported by PCSIRT.

Sign In or Create an Account. Search Dropdown Menu. header search search input Search input auto suggest. filter your search All Content All Journals Cellular Physiology and Biochemistry.

Advanced Search. Toggle Menu Menu. Skip Nav Destination Close navigation menu Article navigation. Volume 38, Issue 5. Metabolic risk factors play a crucial role in the pathogenesis of metabolic hypertension.

The gastrointestinal tract is an important organ involved in metabolic hypertension. Gastrointestinal intervention ameliorates hypertension. Disclosure Statement.

Article Navigation. Review Articles May 03 The Gastrointestinal Tract: an Initial Organ of Metabolic Hypertension? Subject Area: Further Areas. Zhiming Zhu ; Zhiming Zhu. Department of Hypertension and Endocrinology, Center for Hypertension and Metabolic Diseases, Daping Hospital, Third Military Medical University, Chongqing Institute of Hypertension, Chongqing, China.

This Site. Google Scholar. Shiqiang Xiong ; Shiqiang Xiong. Daoyan Liu Daoyan Liu. Cellular Physiology and Biochemistry 38 5 : — Article history Accepted:. Cite Icon Cite. toolbar search Search Dropdown Menu. toolbar search search input Search input auto suggest. View large Download slide.

Table 1 Efficacy for improvement in hypertension by metabolic surgeries [ , ]. View large. View Large. Authors have no conflicts of interest to disclose for this manuscript.

Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J: Global burden of hypertension: analysis of worldwide data. Lancet ; Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ, Comparative Risk Assessment Collaborating G: Selected major risk factors and global and regional burden of disease.

Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, Kastarinen M, Poulter N, Primatesta P, Rodriguez-Artalejo F, Stegmayr B, Thamm M, Tuomilehto J, Vanuzzo D, Vescio F: Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States.

JAMA ; Gao Y, Chen G, Tian H, Lin L, Lu J, Weng J, Jia W, Ji L, Xiao J, Zhou Z, Ran X, Ren Y, Chen T, Yang W, China National D, Metabolic Disorders Study G: Prevalence of hypertension in china: a cross-sectional study.

PLoS One ;8:e Chen X, Wei W, Zou S, Wu X, Zhou B, Fu L, Wang H, Shi J: Trends in the prevalence of hypertension in island and coastal areas of china: a systematic review with meta-analysis. Am J Hypertens ; Lee SR, Cha MJ, Kang DY, Oh KC, Shin DH, Lee HY: Increased prevalence of metabolic syndrome among hypertensive population: ten years' trend of the Korean National Health and Nutrition Examination Survey.

Int J Cardiol ; Zhu Z, Wang P, Ma S: Metabolic hypertension: concept and practice. Front Med ; Abdullaeva GJ, Khamidullaeva GA, Hafizova LS: Significance of salt-sensitivity in risk-stratification in patients with arterial hypertension. Uzbekiston Tibbiet Zhurnali ; Cowley AW, Jr.

Hypertension ; Kannel WB: Blood pressure as a cardiovascular risk factor: prevention and treatment. Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM, American Heart A: Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association.

Hall JE: The kidney, hypertension, and obesity. DeFronzo RA, Ferrannini E: Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care ; Statement on hypertension in diabetes mellitus. Final report.

The Working Group on Hypertension in Diabetes. Arch Intern Med ; Okerson T, Yan P, Stonehouse A, Brodows R: Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes.

Reaven GM: Banting lecture Role of insulin resistance in human disease. Diabetes ; Vogel RA, Corretti MC, Plotnick GD: Effect of a single high-fat meal on endothelial function in healthy subjects. Am J Cardiol ; Williams RR, Hunt SC, Hopkins PN, Stults BM, Wu LL, Hasstedt SJ, Barlow GK, Stephenson SH, Lalouel JM, Kuida H: Familial dyslipidemic hypertension.

Lye HS, Kuan CY, Ewe JA, Fung WY, Liong MT: The improvement of hypertension by probiotics: effects on cholesterol, diabetes, renin, and phytoestrogens. Int J Mol Sci ; Bibbins-Domingo K, Chertow GM, Coxson PG, Moran A, Lightwood JM, Pletcher MJ, Goldman L: Projected effect of dietary salt reductions on future cardiovascular disease.

N Engl J Med ; Sandoval DA, Seeley RJ: Medicine. The microbes made me eat it. Science ; Wang P, Yan Z, Zhong J, Chen J, Ni Y, Li L, Ma L, Zhao Z, Liu D, Zhu Z: Transient receptor potential vanilloid 1 activation enhances gut glucagon-like peptide-1 secretion and improves glucose homeostasis.

Mayer EA: Gut feelings: the emerging biology of gut-brain communication. Nat Rev Neurosci ; Li JV, Ashrafian H, Bueter M, Kinross J, Sands C, le Roux CW, Bloom SR, Darzi A, Athanasiou T, Marchesi JR, Nicholson JK, Holmes E: Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk.

Gut ; Liu L, Liu J, Wong WT, Tian XY, Lau CW, Wang YX, Xu G, Pu Y, Zhu Z, Xu A, Lam KS, Chen ZY, Ng CF, Yao X, Huang Y: Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, Ni Y, Liu D, Zhu Z: Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.

Diabetes Obes Metab ; Linz D, Wirth K, Linz W, Heuer HO, Frick W, Hofmeister A, Heinelt U, Arndt P, Schwahn U, Bohm M, Ruetten H: Antihypertensive and laxative effects by pharmacological inhibition of sodium-proton-exchanger subtype 3-mediated sodium absorption in the gut.

Gutzwiller JP, Tschopp S, Bock A, Zehnder CE, Huber AR, Kreyenbuehl M, Gutmann H, Drewe J, Henzen C, Goeke B, Beglinger C: Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men.

J Clin Endocrinol Metab ; Best JH, Hoogwerf BJ, Herman WH, Pelletier EM, Smith DB, Wenten M, Hussein MA: Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 GLP-1 receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database.

Jackson EK, Mi Z, Tofovic SP, Gillespie DG: Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent. Rodriguez A: Novel molecular aspects of ghrelin and leptin in the control of adipobiology and the cardiovascular system.

Obes Facts ; Bedendi I, Alloatti G, Marcantoni A, Malan D, Catapano F, Ghe C, Deghenghi R, Ghigo E, Muccioli G: Cardiac effects of ghrelin and its endogenous derivatives des-octanoyl ghrelin and des-Glnghrelin. Eur J Pharmacol ; Rodriguez A, Gomez-Ambrosi J, Catalan V, Becerril S, Sainz N, Ramirez B, Salvador J, Diez J, Fortuno A, Fruhbeck G: Vasodilator effect of ghrelin in the rat aorta.

Endocrinol Nutr ; J Cell Biol ; Li WG, Gavrila D, Liu X, Wang L, Gunnlaugsson S, Stoll LL, McCormick ML, Sigmund CD, Tang C, Weintraub NL: Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells.

Circulation ; Rodriguez A, Fruhbeck G, Gomez-Ambrosi J, Catalan V, Sainz N, Diez J, Zalba G, Fortuno A: The inhibitory effect of leptin on angiotensin II-induced vasoconstriction is blunted in spontaneously hypertensive rats.

J Hypertens ; Henriksen JH, Holst JJ, Moller S, Andersen UB, Bendtsen F, Jensen G: Elevated circulating leptin levels in arterial hypertension: relationship to arteriovenous overflow and extraction of leptin.

Clin Sci Lond ; Agata J, Masuda A, Takada M, Higashiura K, Murakami H, Miyazaki Y, Shimamoto K: High plasma immunoreactive leptin level in essential hypertension. Sartor DM: Sympathoinhibitory signals from the gut and obesity-related hypertension. Clin Auton Res ; Dunbar JC, Hu Y, Lu H: Intracerebroventricular leptin increases lumbar and renal sympathetic nerve activity and blood pressure in normal rats.

Fruhbeck G: Pivotal role of nitric oxide in the control of blood pressure after leptin administration. Simonds SE, Pryor JT, Ravussin E, Greenway FL, Dileone R, Allen AM, Bassi J, Elmquist JK, Keogh JM, Henning E, Myers MG, Jr.

Cell ; Kurajoh M, Koyama H, Kadoya M, Naka M, Miyoshi A, Kanzaki A, Kakutani-Hatayama M, Okazaki H, Shoji T, Moriwaki Y, Yamamoto T, Emoto M, Inaba M, Namba M: Plasma leptin level is associated with cardiac autonomic dysfunction in patients with type 2 diabetes: HSCAA study.

Cardiovasc Diabetol ; How JM, Wardak SA, Ameer SI, Davey RA, Sartor DM: Blunted sympathoinhibitory responses in obesity-related hypertension are due to aberrant central but not peripheral signalling mechanisms. J Physiol ; Chen Y, Asico LD, Zheng S, Villar VA, He D, Zhou L, Zeng C, Jose PA: Gastrin and D1 dopamine receptor interact to induce natriuresis and diuresis.

Esler M, Kaye D: Sympathetic nervous system activation in essential hypertension, cardiac failure and psychosomatic heart disease. J Cardiovasc Pharmacol ;S Davy KP, Hall JE: Obesity and hypertension: two epidemics or one? Am J Physiol Regul Integr Comp Physiol ;R Symplicity HTNI, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M: Renal sympathetic denervation in patients with treatment-resistant hypertension The Symplicity HTN-2 Trial : a randomised controlled trial.

Smithwick RH, Thompson JE: Splanchnicectomy for essential hypertension; results in 1, cases. J Am Med Assoc ; How JM, Pumpa TJ, Sartor DM: The circulatory and renal sympathoinhibitory effects of gastric leptin are altered by a high fat diet and obesity. Auton Neurosci ; How JM, Fam BC, Verberne AJ, Sartor DM: High-fat diet is associated with blunted splanchnic sympathoinhibitory responses to gastric leptin and cholecystokinin: implications for circulatory control.

Am J Physiol Heart Circ Physiol ;H Cragg BG, Evans DH: Some reflexes mediated by the afferent fibers of the abdominal vagus in the rabbit and cat. Exp Neurol ; Petkovich BW, Vega J, Thomas S: Vagal modulation of hypertension. Curr Hypertens Rep ; Gautron L, Zechner JF, Aguirre V: Vagal innervation patterns following Roux-en-Y gastric bypass in the mouse.

Int J Obes Lond ; Lutsey PL, Steffen LM, Stevens J: Dietary intake and the development of the metabolic syndrome: the Atherosclerosis Risk in Communities study. The gut microbiome refers to the community of microorganisms residing in our intestines.

Functional medicine utilizes advanced testing to assess the balance and diversity of the gut microbiota, identify potential dysbiosis imbalance , and evaluate markers of gut inflammation and permeability.

Functional medicine's approach to gut health differs from conventional medicine in that it aims to address the root causes of gut imbalances rather than solely managing symptoms. Functional medicine recognizes the interconnectedness of various body systems and the impact of factors like diet, lifestyle, genetics, and comorbid conditions on gut health.

By considering the centrality of gut health in preventing and treating conditions like cardiovascular disease, functional medicine practitioners can design personalized interventions to restore gut balance and positively impact overall health outcomes.

In contrast, conventional medicine often focuses on prescribing medications to manage symptoms without necessarily addressing the underlying causes. While conventional medicine certainly has its merits, functional medicine offers a more holistic and individualized approach to gut health, taking into account the unique needs and circumstances of each patient.

Functional medicine practitioners utilize various tests to assess gut health and gain insights into its impact on overall well-being. Two commonly used tests in functional medicine for assessing gut health are microbiome analysis and comprehensive stool analysis.

Microbiome analysis, such as the GI-MAP by Diagnostic Solutions , employs PCR technology to screen for over 50 beneficial and harmful bacteria, viruses, parasites, and yeast present in the gut.

This analysis provides a comprehensive understanding of the gut microbiome's composition and diversity. Identifying the presence of specific microorganisms can help assess for dysbiosis, an imbalance in the gut microbiota that can contribute to various health issues.

Additionally, microbiome analysis evaluates markers of digestion, absorption, intestinal inflammation, and microbial metabolism, offering valuable insights into gut health as it relates to systemic well-being.

Comprehensive stool analysis, such as the GI Effects Comprehensive Profile by Genova Diagnostics , provides a more detailed assessment of gut health. This test not only analyzes the microbiome's diversity and composition but also measures metabolites like short-chain fatty acids and inflammatory markers such as calprotectin.

These metabolites and markers give insights into the overall health of the gut and can help identify conditions like dysbiosis and intestinal inflammation. Furthermore, an optional add-on for assessing intestinal permeability, such as measuring zonulin levels, can indicate the presence of leaky gut when elevated.

These tests offer valuable insights into the gut's microbial ecosystem, as well as markers of inflammation and intestinal permeability. By understanding the composition of the gut microbiome, identifying potential imbalances and dysfunctions, and assessing markers of gut health, functional medicine practitioners can develop personalized treatment strategies to restore balance and optimize gut function.

These strategies may include dietary modifications, probiotics, and lifestyle changes, all aimed at improving gut health and positively impacting overall well-being, particularly cardiovascular health. The composition of the gut microbiome is highly individualized and can be influenced by various factors, with diet playing a significant role.

It is hypothesized that these enterotypes may impact the development of hypertension in different ways and to varying degrees. For example, certain enterotypes may promote an inflammatory state or produce metabolites that affect blood pressure regulation. While the gut microbiome appears to have a role in the development of hypertension, further research is needed to fully understand the mechanisms involved and develop targeted interventions.

It is essential to explore the specific interactions between the gut microbiota, dietary patterns, genetic factors, and environmental influences to gain a comprehensive understanding of their combined impact on blood pressure regulation.

This knowledge could potentially lead to personalized interventions that target the gut microbiome to prevent or manage hypertension more effectively.

Cloyd, Dr. A Functional Medicine Hypertension Protocol. Rupa Health. Gut Microbiome Testing: How to Use This Powerful Tool in Practice. What is the Gut Microbiome? Functional Medicine for Digestive Wellness in Patients with Heart Disease. Cloyd, J.

How to Heal Your Gut Naturally With Functional Nutrition. DeCesaris, L. What Is Gut Dysbiosis? Jing Lv, Wang, J. Alterations of gut microbiota are associated with blood pressure: a cross-sectional clinical trial in Northwestern China.

Journal of Translational Medicine , 21 1. Jose, P. Gut microbiota in hypertension. Current Opinion in Nephrology and Hypertension , 24 5 , — Neibling, Dr.

Why Functional Medicine Practitioners Focus on Gut Health. Qi, D. The effect of probiotics supplementation on blood pressure: a systemic review and meta-analysis.

Lipids in Health and Disease , Weinberg, Dr. Yoshimura, H. Decoding High Calprotectin Levels: Causes, Implications, and Effective Treatment Strategies.

Documents Tab. Redesigned Patient Portal. Simplify blood panel ordering with Rupa's Panel Builder. Sign in. Sign in Sign up free. Subscribe for free to keep reading!

If you are already subscribed, enter your email address to log back in. Are you a healthcare practitioner? Yes No. Search All Content